The acam2000 market has seen considerable growth due to a variety of factors.
• In recent years, the market size for acam2000 has witnessed a HCAGR of XX. We project that it will expand from $XX million in 2024 to $XX million in 2025, corresponding to a compound annual growth rate (CAGR) of XX%.
Factors contributing to the growth experienced in the historic period include escalated participation in clinical trials, a rise in smallpox instances, growing demand for more aggressive varicella vaccinations, increased funding for vaccine research, and expanded healthcare expenditure.
The acam2000 market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size of acam2000 is predicted to experience a compound annual growth rate (CAGR) of XX%, escalating to reach a valuation of $XX million by 2029.
Factors that contribute to this projected growth during the forecast period include surges in the demand for the coronavirus vaccine, higher rates of vaccination, increase in immunization, development of public health readiness initiatives, and a rising elderly population. The period is also expected to witness trends such as improvements in cell culture and vaccine technologies, enhancements in cold chain logistics, incorporation of AI and machine learning, and innovative product developments.
The surge in smallpox cases is anticipated to stimulate the expansion of the acam2000 market in the future. An increment in smallpox instances, a highly infectious and lethal disease caused by the variola virus, can be ascribed to various aspects like a collapse in immunization drives, intentional dissemination of the virus (bioterrorism), lab mishaps, or the virus transmission through international commuting. ACAM2000 serves as a valuable vaccine that ensures protection against smallpox by bolstering the immune system to combat the virus and avert infection. For example, in August 2024, the Department of Health, a US-based body, reported in August 2022 that cases in the United States peaked, surpassing 30,000 confirmed cases for the year. Hence, the surge in smallpox cases is catalyzing the expansion of the acam2000 market.
The acam2000 market covered in this report is segmented –
1) By Indication: Smallpox, Mpox
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Adults, Geriatric Population
A major trend dominating the ACAM2000 market is a strategic shift towards enhancing vaccine indications aimed at tackling emerging public health menaces like mpox. Corporations are making use of regulatory approvals to extend the application of their vaccines to populations at heightened risk. For example, in August 2024, the US biopharmaceutical firm Emergent BioSolutions Inc. secured approval from the US Food and Drug Administration (FDA) for the supplemental Biologics License Application (sBLA) for ACAM2000 (Smallpox and Mpox [Vaccinia] Vaccine, Live). This seeks to increase its indication to include the prevention of pox for individuals highly susceptible to infection. The endorsement is backed by existing human safety data and proof from a regulated animal study showing the vaccine's effectiveness in offering protection against mpox virus exposure.
Major companies operating in the acam2000 market include:
• Emergent BioSolutions Inc.
North America was the largest region in the acam2000 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acam2000 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.